News
Novo Nordisk and Eli Lilly (NYSE:LLY) shares edged higher Tuesday following results from Viking Therapeutics’ Phase 2 VENTURE-Oral Dosing trial for its oral obesity treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback